大剂量静脉羟钴胺(维生素B12)治疗脓毒性休克:双盲、分配隐藏、安慰剂对照单中心先导随机对照试验(静脉羟钴胺治疗脓毒性休克试验)
该单中心、双盲、分配隐藏、安慰剂对照、平行组2期先导RCT纳入符合Sepsis 3标准的脓毒性休克成人,1:1随机接受单次5g静脉羟钴胺或等体积0.9%氯化钠安慰剂。主要终点为可行性(入组率、临床与实验室依从率、污染率),19个月入组20例,入组率1.05例/月,方案依从率100%,污染率为零。次要终点显示羟钴胺组随机化至输注后血管活性药剂量降幅大于安慰剂组(-36% vs 4%,P<.001),随机化至输注后3小时降幅亦更大(-28% vs 10%,P=.019);血浆H2S水平45分钟内下降-0.80±1.73 μM vs -0.21±0.64 μM(P=.3)。作者认为该先导试验证实了可行性,并首次提供大剂量静脉羟钴胺治疗脓毒性休克的概念验证数据。
要点
- 单中心先导RCT:脓毒性休克成人单次静脉5g羟钴胺 vs 等体积0.9%氯化钠,19个月入组20例,入组率1.05例/月。
- 可行性指标:方案依从率100%,污染率为零,支持后续开展更大规模试验。
- 血管活性药剂量:随机化至输注后羟钴胺组-36% vs 安慰剂组4%(P<.001);至输注后3小时-28% vs 10%(P=.019)。
- 血浆H2S水平45分钟内变化:羟钴胺组-0.80±1.73 μM vs 安慰剂组-0.21±0.64 μM(P=.3),未达统计学显著。
- 作者报告无严重不良事件,并称该数据为大剂量静脉羟钴胺用于脓毒性休克的首个可行性概念验证。
适用人群与场景
- 符合Sepsis 3标准的成人脓毒性休克患者,来自单中心重症监护环境。
诊断标准与关键阈值
- 纳入标准:符合Sepsis 3标准的成人脓毒性休克患者。
处置流程与药物剂量
- 随机1:1接受单次5g静脉羟钴胺或等体积0.9%氯化钠溶液安慰剂。
研究设计与关键结果
- 研究类型:2期单中心、双盲、分配隐藏、安慰剂对照、平行组先导随机对照试验;样本量20例;19个月入组,入组率1.05例/月。
- 干预与对照:单次5g静脉羟钴胺 vs 等体积0.9%氯化钠安慰剂。
- 主要终点可行性:方案依从率100%,污染率为零。
- 次要终点血管活性药剂量:随机化至输注后羟钴胺组-36% vs 安慰剂组4%(P<.001);随机化至输注后3小时羟钴胺组-28% vs 安慰剂组10%(P=.019)。
- 次要终点血浆H2S:45分钟内羟钴胺组下降-0.80±1.73 μM vs 安慰剂组-0.21±0.64 μM(P=.3)。
- 不良事件:作者报告无严重不良事件。
证据类型、等级与局限
- 证据类型:单中心先导随机对照试验(2期)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该先导试验证实了大剂量静脉羟钴胺在脓毒性休克中给药的可行性,并首次提供概念验证数据;血管活性药剂量下降与H2S水平降低的结果与预设机制一致。
指南或共识出处
- 临床试验注册:ClinicalTrials.gov,注册号NCT03783091。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Elevated hydrogen sulfide (H2S) contributes to vasodilatation and hypotension in septic shock, and traditional therapies do not target this pathophysiologic mechanism. High-dose IV hydroxocobalamin scavenges and prevents H2S formation, which may restore vascular tone and may accentuate recovery. No experimental human studies have tested high-dose IV hydroxocobalamin in adults with septic shock.
RESEARCH QUESTION: In adults with septic shock, is comparing high-dose IV hydroxocobalamin with placebo feasible?
STUDY DESIGN AND METHODS: We conducted a phase 2 single-center, double-blind, allocation-concealed, placebo-controlled, parallel-group pilot randomized controlled trial comparing high-dose IV hydroxocobalamin with placebo in critically ill adults with septic shock. Patients meeting Sepsis 3 criteria were randomized 1:1 to receive a single 5-g dose of high-dose IV hydroxocobalamin or equivalent volume 0.9% saline solution as placebo. The primary outcome was study feasibility (enrollment rate, clinical and laboratory compliance rate, and contamination rate). Secondary outcomes included between-group differences in plasma H2S concentrations and vasopressor dose before and after infusion.
RESULTS: Twenty patients were enrolled over 19 months, establishing an enrollment rate of 1.05 patients per month. Protocol adherence rates were 100% with zero contamination. In the high-dose IV hydroxocobalamin group, compared to placebo, there was a greater reduction in vasopressor dose between randomization and postinfusion (-36% vs 4%, P < .001) and randomization and 3-h postinfusion (-28% vs 10%, P = .019). In the high-dose IV hydroxocobalamin group, the plasma H2S level was reduced over 45 mins by -0.80 ± 1.73 μM, as compared with -0.21 ± 0.64 μM in the placebo group (P = .3).
INTERPRETATION: This pilot trial established favorable feasibility metrics. Consistent with the proposed mechanism of benefit, high-dose IV hydroxocobalamin compared with placebo was associated with reduced vasopressor dose and H2S levels at all time points and without serious adverse events. These data provide the first proof of concept for feasibility of delivering high-dose IV hydroxocobalamin in septic shock.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03783091; URL: www.
CLINICALTRIALS: gov.
参考来源
- Patel JJ, Willoughby R, Peterson J, et al. High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial). Chest. 2022. PMID: 36174744. doi:10.1016/j.chest.2022.09.021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。